89bio, INC 8-K filings

89bio, Inc. has completed its merger with Roche Holdings, Inc., becoming a wholly-owned subsidiary and initiating its delisting from The Nasdaq Global Market.

Roche Holdings, Inc. will acquire 89bio, Inc. for $14.50 per share in cash plus a contingent value right of up to $6.00 per share, totaling up to $3.5 billion.

89bio, Inc. announced Q2 2025 financial results and provided updates on its Phase 3 trials for pegozafermin in MASH and SHTG, with key data expected in 2026-2028.

89bio, Inc. announced that all director nominees were elected and all proposals, including the ratification of KPMG LLP as independent auditor and the advisory vote on executive compensation, were approved at its 2025 Annual Meeting of Stockholders.

89bio announces its Q1 2025 financial results, highlighting progress in Phase 3 trials for MASH and SHTG, and a strong cash position following a recent equity offering.

89bio provides an update on its corporate presentation, emphasizing the potential of Pegozafermin in treating MASH with advanced fibrosis and compensated cirrhosis, as well as severe hypertriglyceridemia (SHTG).

89bio announces its Q4 and full year 2024 financial results, highlighting progress in its Phase 3 trials for MASH and SHTG, and provides updates on regulatory feedback and cash position.

89bio, Inc. announced the grant of 200,000 restricted stock units (RSUs) to Chief Executive Officer Rohan Palekar, vesting semi-annually over two years.

89bio, Inc. has entered into an underwriting agreement for a public offering of common stock and pre-funded warrants, expected to generate approximately $234.6 million in net proceeds.

89bio reports successful completion of enrollment in a Phase 3 trial for severe hypertriglyceridemia and provides a business update, including approximately $440 million in cash reserves.

89bio, Inc.'s Board of Directors approved the grant of restricted stock units to key executives for retention purposes.

89bio, Inc. has entered into an underwriting agreement to sell 11,455,882 shares of common stock and pre-funded warrants to purchase 3,250,000 shares, expecting net proceeds of approximately $118.4 million.

89bio announced its third quarter 2024 financial results, highlighting progress in its Phase 3 clinical trials and strategic leadership appointments.

89bio, Inc. has filed an amendment to its previous 8-K report to disclose the committee assignments for newly appointed board member, Dr. Charles McWherter.

89bio, Inc. has amended its loan agreement to increase its borrowing capacity to $150 million and issued warrants to purchase common stock to K2 HealthVentures.

89bio, a clinical-stage biopharmaceutical company, has appointed Francis Sarena as its new Chief Operating Officer, effective August 5, 2024, to support its Phase 3 clinical program and commercialization efforts.

89bio reported its Q2 2024 financial results, initiated two Phase 3 trials for MASH, and appointed Dr. Charles McWherter to its Board of Directors.

89bio, Inc. successfully held its 2024 Annual Meeting, electing directors and approving all proposals, including the ratification of KPMG LLP as independent auditor.

89bio initiated a Phase 3 trial for MASH and is on track to begin another trial this quarter, while also reporting increased R&D spending and a net loss for the first quarter of 2024.

89bio, a clinical-stage biopharmaceutical company, has appointed Martin Babler, a seasoned biotech executive, to its Board of Directors, effective April 13, 2024.

89bio has entered into a collaboration agreement with BiBo Biopharma to construct a dedicated production facility for pegozafermin, with 89bio committing $135 million towards the project.

89bio announced its full year 2023 financial results, highlighted positive clinical trial data for pegozafermin, and outlined plans to initiate Phase 3 trials for NASH.